Tessera Diagnostics Inc.
This article was originally published in Start Up
Executive Summary
Tessera Diagnostics, founded in December 2000, is focusing on developing a group of protein markers for early detection of cancer. It's first indication is prostate cancer, and it has in-licensed a group of 14 markers from a family of proteins called NMPs for early detection of the disease. It believes some of these markers are specific and highly sensitive to the disease, and as a group they will provide better information than any test currently available.
You may also be interested in...
Overcoming Skepticism About Cancer Diagnostics
In cancer diagnostics skepticism and optimism exist side by side. This is evident from a growing dichotomy between the spurt of early research projects, fueled by new technologies and increased government spending, and the lack of investor interest. Despite a brutal financing market and past disappointments, a few start-ups determined to address the field's unmet needs are pursuing development of new markers and detection technologies and gaining momentum.
A Business in Cancer Susceptibility Testing?
Making money in cancer susceptibility testing has been tough; all eyes are on Myriad.
Diagnostic Destinies in Seattle
In one month, in Seattle, two diagnostics companies, generic glucose strip maker Polymer Technologies and osteoporosis test maker Ostex International, both saw their businesses radically changed by Johnson & Johnson--the first nearly destroyed, the second boosted.